BridgeBio Pharma, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $208.52Mn |
Net Profits | $-152.22Mn |
Net Profit Margins | -73% |
BridgeBio Pharma, Inc. Common Stock’s revenue jumped 88.6% since last year same period to $208.52Mn in the Q2 2026. On a quarterly growth basis, BridgeBio Pharma, Inc. Common Stock has generated 7.2% jump in its revenue since last 3-months.
BridgeBio Pharma, Inc. Common Stock’s net profit jumped 16.32% since last year same period to $-152.22Mn in the Q2 2026. On a quarterly growth basis, BridgeBio Pharma, Inc. Common Stock has generated 7.21% jump in its net profits since last 3-months.
BridgeBio Pharma, Inc. Common Stock’s net profit margin jumped 55.63% since last year same period to -73% in the Q2 2026. On a quarterly growth basis, BridgeBio Pharma, Inc. Common Stock has generated 13.44% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.64 |
EPS Estimate Current Year | -0.64 |
BridgeBio Pharma, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.64 - a -3.23% fall from last quarter’s estimates.
BridgeBio Pharma, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.64.
Key Ratios
Earning Per Share (EPS) | -0.78 |
BridgeBio Pharma, Inc. Common Stock’s earning per share (EPS) jumped 17.89% since last year same period to -0.78 in the Q2 2026. This indicates that the BridgeBio Pharma, Inc. Common Stock has generated 17.89% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-10 | -0.64 | -0.78 | -21.88% |
2026-05-07 | -0.62 | -0.84 | -35.48% |
